Shares of Nextgen Healthcare Inc (NASDAQ:NXGN) have received an average broker rating score of 2.85 (Hold) from the thirteen brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong sell rating, eight have assigned a hold rating and three have assigned a strong buy rating to the company. Nextgen Healthcare’s rating score has improved by 7.8% in the last 90 days as a result of various analysts’ ratings changes.

Brokerages have set a twelve-month consensus target price of $18.38 for the company and are expecting that the company will post $0.15 earnings per share for the current quarter, according to Zacks. Zacks has also given Nextgen Healthcare an industry rank of 102 out of 256 based on the ratings given to its competitors.

Several research firms recently commented on NXGN. Dougherty & Co raised Nextgen Healthcare from a “neutral” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Friday. Zacks Investment Research upgraded Nextgen Healthcare from a “sell” rating to a “hold” rating in a research note on Monday, January 7th. Cantor Fitzgerald reiterated a “buy” rating and issued a $23.00 price target on shares of Nextgen Healthcare in a research report on Thursday, December 6th. TheStreet cut Nextgen Healthcare from a “b-” rating to a “c+” rating in a research report on Wednesday, November 21st. Finally, Morgan Stanley upgraded Nextgen Healthcare from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $12.00 to $16.00 in a research report on Thursday, November 1st.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXGN. Bank of Montreal Can bought a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at about $165,000. BlueMountain Capital Management LLC bought a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at about $205,000. Quantbot Technologies LP bought a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at about $207,000. Hanson & Doremus Investment Management bought a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at about $208,000. Finally, Piedmont Investment Advisors Inc. bought a new stake in shares of Nextgen Healthcare in the 3rd quarter valued at about $222,000. 68.73% of the stock is owned by institutional investors.

NXGN opened at $16.66 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.12. Nextgen Healthcare has a 52-week low of $12.24 and a 52-week high of $23.73. The firm has a market cap of $1.03 billion, a PE ratio of 29.23, a P/E/G ratio of 3.15 and a beta of 1.07.

Nextgen Healthcare (NASDAQ:NXGN) last posted its earnings results on Tuesday, October 30th. The company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.19 by $0.05. The firm had revenue of $130.30 million during the quarter, compared to the consensus estimate of $134.55 million. Nextgen Healthcare had a return on equity of 10.23% and a net margin of 1.17%. The business’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the company earned $0.22 earnings per share. Equities analysts forecast that Nextgen Healthcare will post 0.57 earnings per share for the current year.

Nextgen Healthcare Company Profile

NextGen Healthcare, Inc provides software, services, and analytics solutions to medical and dental group practices in the United States. The company's principal products include NextGen Enterprise EHR, which stores and maintains clinical patient information; and a workflow module, prescription management, automatic document and letter generation, patient education, referral tracking, interfaces to billing and lab systems, physician alerts and reminders, and reporting and data analysis tools.

Featured Story: Diversification For Individual Investors

Get a free copy of the Zacks research report on Nextgen Healthcare (NXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Nextgen Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nextgen Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.